晋景新能(01783)再涨超7%，截至发稿，涨7%，报8.86港元，成交额1624.56万港元。 消息面上，8月22日盘后，恒生指数公司公布了其定期的半年度指数调整结果，其中晋景新能获纳入恒 生综合指数成分股，变动将于9月5日收市后实施并于9月8起生效。此前，瑞银、中金及申万宏源预计晋 景新能有望纳入港股通名单标的。分析人士指出，入通后晋景新能有望获得更多南向资金的关注、青 睐，以及被动资金如指数基金的增配，短期流动性便将显著提升。 ...

Core Viewpoint - The inclusion of Jin Jing New Energy in the Hang Seng Composite Index is expected to enhance its liquidity and investment value, marking a significant opportunity for value reassessment [1][2][3]. Group 1: Impact of Inclusion in the Hang Seng Index - The inclusion in the Hang Seng Composite Index will attract passive fund allocations, leading to substantial capital inflow for Jin Jing New Energy [2][3]. - The index's strict selection criteria reflect the company's market value and growth potential, providing authoritative recognition [2]. - The potential inclusion in the Stock Connect program will further broaden the company's funding sources and valuation space [3]. Group 2: Growth Potential and Industry Position - Jin Jing New Energy is uniquely positioned in the Hong Kong market as the only overseas battery recycling stock, with over 70 service outlets across 28 countries [5]. - The company has established strong partnerships with industry leaders, enhancing its market share and growth prospects [5]. - The company's revenue surged by 92.3% year-on-year to HKD 870 million, with a gross profit increase of 266.8%, indicating strong business performance [6]. Group 3: Market Trends and Future Outlook - The electric vehicle penetration rate in Hong Kong is projected to rise significantly, creating substantial demand for battery recycling [7]. - The Hong Kong government's policies on electric vehicle adoption and waste management will further support the growth of the battery recycling market [7]. - Jin Jing New Energy is set to operate Hong Kong's first battery processing facility, positioning itself advantageously in the market [7]. Group 4: Conclusion - The global energy transition presents historic opportunities for green technology companies, with Jin Jing New Energy poised to benefit from increased liquidity and valuation reassessment [8].

Group 1 - The core point of the article is that Jin Jing New Energy (01783) has seen a significant stock price increase due to its inclusion in the Hang Seng Composite Index, which is expected to enhance liquidity and attract more investment from mainland China [1][1][1] Group 2 - Jin Jing New Energy's stock price rose over 8% during trading, with a current increase of 6.3%, reaching HKD 8.1, and a trading volume of HKD 10.67 million [1][1][1] - The announcement of the index adjustment was made by the Hang Seng Index Company on August 22, with the changes set to take effect after market close on September 5 and officially on September 8 [1][1][1] - Analysts from UBS, CICC, and Shenwan Hongyuan have predicted that Jin Jing New Energy is likely to be included in the Hong Kong Stock Connect list, which would unlock a direct inflow channel for mainland funds [1][1][1]

晋景新能(01783)盘中涨超8%，截至发稿，涨6.3%，报8.1港元，成交额1067.65万港元。 消息面上，8月22日盘后，恒生指数公司公布了其定期的半年度指数调整结果，其中晋景新能获纳入恒 生综合指数成分股，变动将于9月5日收市后实施并于9月8起生效。此前，瑞银、中金及申万宏源预计晋 景新能有望纳入港股通名单标的。分析人士指出，一旦入港股通，晋景新能将直接解锁内地资金的流入 通道，有望获得更多南向资金的关注、青睐，以及被动资金如指数基金的增配，短期流动性便将显著提 升。 ...

消息面上，恒生指数公司8月22日晚宣布截至2025年6月30日的恒生指数系列季度检讨结果，其中，晋景 新能(1783.HK)获纳入恒生综合指数，变动将于9月5日(星期五)收市后实施，并于9月8日(星期一)起生 效。届时沪深交易所会相应调整港股通可投资标的范围。此前，包括华泰证券、申万宏源、国证国际在 内的多家机构均预期晋景新能有望获纳入港股通。 格隆汇8月25日｜晋景新能(1783.HK)盘初拉升涨近9%，报8.3港元。 ...

业绩方面，6月25日，商晋景新能发布了2025财年(截至3月31日止12个月)的业绩公告。数据显示，公司 报告期内的收入约为8.7亿(港元，下同)，同比大增92.3%。若剔除若干项不反映业务持续经营表现的一 次性开支后，晋景新能2025财年已实现盈利。报告期内，晋景新能的经调整EBITDA录得盈利4476.4万 元。 分析人士指出，一旦入港股通，晋景新能将直接解锁内地资金的流入通道，有望获得更多南向资金的关 注、青睐，以及被动资金如指数基金的增配，短期流动性便将显著提升。 8月22日，恒生指数公司公布最新季检结果，其中晋景新能(01783)获纳入恒生综合指数成份股，所有变 动将于2025年9月5日(星期五)收市后实施并于2025年9月8日(星期一)起生效。此前，瑞银、中金及申万 宏源预计晋景新能有望纳入港股通名单标的。 ...

业绩方面，6月25日，商晋景新能发布了2025财年(截至3月31日止12个月)的业绩公告。数据显示，公司 报告期内的收入约为8.7亿(港元，下同)，同比大增92.3%。若剔除若干项不反映业务持续经营表现的一 次性开支后，晋景新能2025财年已实现盈利。报告期内，晋景新能的经调整EBITDA录得盈利4476.4万 元。 智通财经APP获悉，8月22日，恒生指数公司公布最新季检结果，其中晋景新能(01783)获纳入恒生综合 指数成份股，所有变动将于2025年9月5日(星期五)收市后实施并于2025年9月8日(星期一)起生效。此 前，瑞银、中金及申万宏源预计晋景新能有望纳入港股通名单标的。 分析人士指出，一旦入港股通，晋景新能将直接解锁内地资金的流入通道，有望获得更多南向资金的关 注、青睐，以及被动资金如指数基金的增配，短期流动性便将显著提升。 ...

今日下午，恒生指数公司发布季检结果，晋景新能、宁德时代、曹操出行、中国食品、恒瑞医药、周六福等24股获纳入恒生综合指数。 | 代號 | 公司 | | | --- | --- | --- | | 6168 | 周六福珠竇股份有限公司 - H 股 | | | 6603 | IFBH Ltd. - F | | | 6681 | 腦動極光醫療科技有限公司 - B | | | 6993 | 藍月亮集團控股有限公司 | | | aeoe | 映恩生物 - B | | | 9678 | 婴知聲智能科技股份有限公司 - H 股 | 写同 | | 代號 | 公司 | | --- | --- | | 506 | 中國食品有限公司 | | 1276 | 江蘇恒瑞醫藥股份有限公司 - H 股 | | 1333 | 博雷頓科技股份公司 - H 股 | | 1729 | 匯聚科技有限公司 | | 1783 | 晋景新能控股有限公司 | | 2007 | 碧桂園控股有限公司 | | 2050 | 浙江三花智能控制股份有限公司 - H 股 | | 2276 | 上海康耐特光學科技集團股份有限公司 - H 股 | | 2473 | 喜相逢集團 ...

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]